ethyl bis(4-methylphenyl)phosphite | 83877-25-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: ethyl bis(4-methylphenyl)phosphite
• 英文别名: ethyl di-p-tolylphosphite；Ethyl bis(4-methylphenyl) phosphite
• CAS: 83877-25-2
• 化学式: C₁₆H₁₉O₃P
• 分子量: 290.299
• InChiKey: VSKURMGPRIUQDS-UHFFFAOYSA-N

物化性质

• 沸点：
  125 °C(Press: 0.01 Torr)

计算性质

• 辛醇/水分配系数(LogP)：
  4.8
• 重原子数：
  20
• 可旋转键数：
  6
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  27.7
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  ethyl bis(4-methylphenyl)phosphite 在 碳酸氢钠 作用下， 以 水 为溶剂， 反应 24.0h， 生成 sodium p-tolyl phenoxycarbonylphosphonate
  参考文献：
  名称：

  Synthesis of esters of phosphonoformic acid and their antiherpes activity

  摘要：

  Aliphatic and aromatic mono-, di-, and triesters of phosphonoformic acid (foscarnet) were synthesized. The triesters were prepared by the Michaelis-Arbuzov reaction and were hydrolyzed to di- and monoesters. The compounds were tested for antiviral activity on isolated herpes simplex virus type 1 (HSV-1) DNA polymerase, in a HSV-1 plaque reduction assay, and on a cutaneous HSV-1 infection in guinea pigs. None of the esters inhibited the activity of isolated HSV-1 polymerases. Monoesters with a free carboxylic group and diesters with an aromatic carboxylic ester function were active against the cutaneous herpes infection. Mono- and diesters with an aromatic phosphonic ester group also showed activity in the plaque-reduction assay. However, mono- and diesters with an aromatic phosphonic ester group also showed activity in the plaque-reduction assay. However, mono- and diesters with aliphatic carboxylic ester groups were inactive in all test systems. The results show that all three acidic groups of phosphonoformic acid must be free in order to get antiviral activity at the enzyme level. However, certain esters of this acid may be biotransformed to the acid itself to give antiherpes activity.

  DOI：

  10.1021/jm00356a028
• 作为产物：
  描述：

  chloro-bis-p-tolyloxy-phosphine 在 吡啶 作用下， 以 乙醇 、 正己烷 为溶剂， 以69%的产率得到ethyl bis(4-methylphenyl)phosphite
  参考文献：
  名称：

  Phosphonoformic acid esters

  摘要：

  式##STR1##的化合物，其中R.sub.1、R.sub.2和R.sub.3相同或不同，且每个均选自由氢和苯基组成的群，该群的式为##STR2##，其中R.sub.4和R.sub.5相同或不同，每个均选自由氢、卤素、具有1、2或3个碳原子的烷基、具有1、2或3个碳原子的烷氧基、具有2-7个碳原子的烷氧羰基；和具有2-7个碳原子的烷基羰基；或者R.sub.4和R.sub.5一起形成直链饱和的具有3或4个碳原子的烷基链，并与相邻位置即苯环中的2,3-或3,4-相连；前提是当R.sub.3为H时，R.sub.1和R.sub.2中的一个是式II的苯基；以及其生理上可接受的盐和光学异构体；制备这些化合物的方法，含有它们的药物组合物，以及它们的药用。

  公开号：

  US04372894A1

文献信息

• The β-(Phosphatoxy)alkyl Radical Rearrangement. Rate Constants, Arrhenius Parameters, and Structure Activity Relationships
  作者：David Crich、Xian-Yun Jiao

  DOI：10.1021/ja961275a

  日期：1996.1.1

  Rate constants for the migration of a series of p,p-disubstituted β-(diarylphosphatoxy)alkyl migrations have been determined in benzene at reflux by competition against the benzeneselenol clock reaction. There is a strong linear correlation of log(k) with the Hammett σp but not with various σ• parameters indicating that the migration occurs through a highly polarized transition state resembling an

  通过与苯硒醇时钟反应的竞争，在回流的苯中确定了一系列 p,p-二取代 β-(二芳基磷酸酯氧基) 烷基迁移的速率常数。log(k) 与 Hammett σp 有很强的线性相关性，但与各种 σ• 参数无关，表明迁移是通过高度极化的过渡态发生的，类似于松散结合到磷酸根阴离子的烯烃自由基阳离子。发现描述 β-苯基-β-（二苯基磷酸酯氧基）乙基自由基在甲苯中迁移的阿伦尼乌斯方程为 log(kR) = (10.2 ± 0.8) - (7.0 ± 1.0)/2.3RT。
• Rhodium recovery from hydroformylation still heel with triaryl phosphate ligand
  申请人：E.I. DU PONT DE NEMOURS AND COMPANY

  公开号：EP0000665A1

  公开（公告）日：1979-02-07

  A process for recovering rhodium present in a still heel from the hydroformylation of an unsaturated hydrocarbon wherein rhodium and a triaryl phosphite ligand were used by a process comprising a) pretreating the still heel with a compatible organic solvent, at least 5 ml of water per 100 g of still heel, oxygen gas or a precursor thereof and sufficient base to produce a pH of 2 to 7 in the reaction mixture after rhodium precipitation; b) heating to a temperature of from 0° to 80°C to oxidize the triaryl phosphite ligand to the corresponding phosphate compound; c) heating the mixture from b) for from about 15 minutes to about 120 minutes at about 115°C to about 175°C to precipitate the rhodium and optionally purifying the rhodium from c) by d) separating the rhodium precipitate; e) washing the rhodium precipitate with a solvent-acid solution at a pH of to4; f) treating the rhodium precipitate with an alkaline reducing solution to reduce the trivaient rhodium impurity to zero valent rhodium; g) quenching the rhodium with glacial acetic acid; h) separating the rhodium; i) washing the rhodium with an acid solution at a pH of 3 to 4; j) drying the rhodium in an inert atmosphere at from 250° to 400°C; and k) oxidizing the rhodium at a temperature of from 300° to 900°C to convert the rhodium to Rh2O3.

  一种回收不饱和烃加氢甲酰化反应生成的静止馏分中的铑的工艺，其中使用了铑和三芳基亚磷酸配体，该工艺包括 a) 用相容的有机溶剂、每 100 克蒸馏水中至少 5 毫升的水、氧气或其前体和足够的碱对蒸馏水进行预处理，使铑沉淀后反应混合物的 pH 值为 2 至 7； b) 加热至 0° 至 80°C 的温度，将三芳基亚磷酸配体氧化成相应的磷酸盐化合物； c) 将来自 b) 的混合物在约 115°C 至约 175°C 的温度下加热约 15 分钟至约 120 分钟，以沉淀铑，并可选择通过以下方式纯化来自 c) 的铑 d) 分离铑沉淀； e) 用 pH 值为 4 以下的溶剂-酸溶液洗涤铑沉淀； f) 用碱性还原溶液处理铑沉淀，将三价铑杂质还原为零价铑； g) 用冰醋酸淬灭铑； h) 分离铑 i) 用 pH 值为 3-4 的酸性溶液洗涤铑； j) 在 250° 至 400°C 的惰性气氛中干燥铑；以及 k) 在 300° 至 900°C 的温度下氧化铑，将铑转化为 Rh2O3。
• Aromatic derivatives of phosphonoformic acid, processes for their preparation, pharmaceutical compositions containing them and their use for combating virus infections
  申请人：Astra Läkemedel Aktiebolag

  公开号：EP0003275A1

  公开（公告）日：1979-08-08

  A compound of the formula wherein R,, R2 and R3 are the same or different, and each is selected from the group consisting of hydrogen and phenyl groups of the formula wherein R4 and R5 are the same or different and each is. selected from the group consisting of hydrogen, halogen, alkyl having 1; 2, or 3 carbon atoms, alkoxy having 7,2. or 3 carbon atoms, alkoxycarbonyl having 2-7 carbon atoms; and alkylcarbonyl groups having 2-7 carbon atoms; or R4 and R5 together form a straight saturated alkylene chain having 3 or 4 carbon atoms and being bound to adjacent positions, i.e. 2,3- or 3,4- in the phenyl ring; provided that one of R1 and R2 is a phenyl group of the formula II when R3 is H; and physiologically acceptable salts and optical isomers thereof; methods for preparation of the compounds, pharmaceutical compositions containing them, and their medicinal use.

  式中的化合物 其中 R、R2 和 R3 相同或不同，且各自选自由氢和式中的苯基组成的组 其中 R4 和 R5 相同或不同，且各自选自由氢、卤素、具有 1；2 或 3 个碳原子的烷基、具有 7、2. 或 3 个碳原子的烷氧基、具有 2-7 个碳原子的烷氧羰基；以及具有 2-7 个碳原子的烷基羰基组成的组；或 R4 和 R5 共同形成具有 3 或 4 个碳原子的直饱和亚烷基链，并与相邻位置结合，即即苯基环中的2,3-或3,4-；条件是当R3为H时，R1和R2中的一个是式II的苯基；以及它们的生理上可接受的盐和光学异构体；化合物的制备方法、含有它们的药物组合物及其药用用途。
• NOREN, J. O.;HELGSTRAND, E.;JOHANSSON, N. G.;MISIORNY, A.;STENING, G., J. MED. CHEM., 1983, 26, N 2, 264-270
  作者：NOREN, J. O.、HELGSTRAND, E.、JOHANSSON, N. G.、MISIORNY, A.、STENING, G.

  DOI：——

  日期：——
• CURABLE COMPOSITION AND CURED PRODUCT THEREOF
  申请人：Kaneka Corporation

  公开号：EP2341106B1

  公开（公告）日：2013-05-29